A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
NCT ID: NCT04094519
Last Updated: 2024-11-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
24 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-01-27
Study Completion Date
2020-12-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary purpose of this study is to determine the effect of multiple once daily administrations of enzalutamide on the pharmacokinetics of a single dose of digoxin (P-glycoprotein (P-gp) substrate) and rosuvastatin (breast cancer resistant protein (BCRP) substrate) in participants with prostate cancer.
This study will also evaluate the safety and tolerability of multiple once daily administrations of enzalutamide alone and in combination with a single dose of digoxin (P-gp substrate) and rosuvastatin (BCRP substrate) in participants with prostate cancer, as well, assess the pharmacokinetics of enzalutamide and its active metabolite.
This study will also evaluate the safety and tolerability of multiple once daily administrations of enzalutamide alone and in combination with a single dose of digoxin (P-gp substrate) and rosuvastatin (BCRP substrate) in participants with prostate cancer, as well, assess the pharmacokinetics of enzalutamide and its active metabolite.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
NCT01995513
Prostate Cancer
COMPLETED
PHASE4
Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide
NCT01091103
Metastatic Progressive Castration-resistant Prostate Cancer
COMPLETED
PHASE2
A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
NCT01302041
Prostate Cancer
COMPLETED
PHASE2
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
NCT01547299
Prostate Cancer
COMPLETED
PHASE2
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
NCT00165399
Adenocarcinoma of the Prostate
Prostate Cancer
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible participants will be admitted to the clinical unit on day -1. Participants may be discharged from the clinical unit on day 2 on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit and participants are able and willing to return to the clinical unit on days 3 to 8 for daily pharmacokinetic sampling. Or, participants may choose to remain in the clinical unit up to the 168 hour postdose (day 8) pharmacokinetic sample collection.
Participants will return to the clinical unit on day 35 for an ambulant visit and will be admitted to the clinical unit on day 63. Participants may be discharged from the clinical unit on day 65 on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit and participants are able and willing to return to the clinical unit on days 66 to 71 for daily pharmacokinetic sampling. Or, participants may choose to remain in the clinical unit up to the 168 hour postdose (day 71) pharmacokinetic sample collection.
From day 72 onwards, participants experiencing clinical benefit (determined by the investigator in consultation with the physician responsible for treating the participants' prostate cancer) may roll over into an open label, single arm extension study. Only participants who will be enrolled into the extension study will continue to receive enzalutamide until any discontinuation criterion occurs per the extension study protocol.
Participants will return to the clinical unit on day 35 for an ambulant visit and will be admitted to the clinical unit on day 63. Participants may be discharged from the clinical unit on day 65 on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit and participants are able and willing to return to the clinical unit on days 66 to 71 for daily pharmacokinetic sampling. Or, participants may choose to remain in the clinical unit up to the 168 hour postdose (day 71) pharmacokinetic sample collection.
From day 72 onwards, participants experiencing clinical benefit (determined by the investigator in consultation with the physician responsible for treating the participants' prostate cancer) may roll over into an open label, single arm extension study. Only participants who will be enrolled into the extension study will continue to receive enzalutamide until any discontinuation criterion occurs per the extension study protocol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Prostate Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
digoxin plus rosuvastatin and enzalutamide
Participants will receive a single oral dose cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin on Day 1 and 64. A single oral dose of placebo to match enzalutamide will be given on Day 1 and 160 mg enzalutamide once daily on Days 8 through 71.
Group Type
EXPERIMENTAL
enzalutamide
Intervention Type
DRUG
oral
enzalutamide Placebo
Intervention Type
DRUG
oral
digoxin
Intervention Type
DRUG
oral
rosuvastatin
Intervention Type
DRUG
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
enzalutamide
oral
Intervention Type
DRUG
enzalutamide Placebo
oral
Intervention Type
DRUG
digoxin
oral
Intervention Type
DRUG
rosuvastatin
oral
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
ASP9785
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
* Subject has a serum testosterone level \< 1.7 nmol/L (50 ng/dL) during the screening period if under androgen deprivation therapy (ADT).
* Subject has newly diagnosed metastatic prostate cancer or progressive disease on ADT confirmed by prostate-specific antigen (PSA) or imaging. Disease progression at screening is defined as 1 or more of the following 3 criteria:
* PSA progression defined by a minimum of 2 rising PSA levels with an interval of ≥ 1 week between each determination. At least 1 PSA value within the 3 months leading up to the screening period should be ≥ 2μg/L (2 ng/mL).
* Soft tissue disease progression defined by the Response Evaluation Criteria in Solid Tumors, version 1.1 for soft tissue disease.
* Bone disease progression defined by 2 or more new lesions on a bone scan.
* Subject is able to swallow enzalutamide capsules and comply with study requirements.
* Subject has an Eastern Cooperative Oncology Group performance status of 0 to 2.
* Subject with a female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 3 months after final investigational product (IP) administration.
* Subject must not donate sperm during the treatment period and for 3 months after final IP administration.
* Subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 3 months after final IP administration.
* Subject has a body mass index range of 18.5 to 35.0 kg/m2 inclusive. The subject weighs at least 50 kg at screening.
* Subject has an estimated life expectancy of at least 6 months.
* Subject agrees not to participate in another interventional study while receiving IP treatment in the present study/participating in the present study.
* Subject has a serum testosterone level \< 1.7 nmol/L (50 ng/dL) during the screening period if under androgen deprivation therapy (ADT).
* Subject has newly diagnosed metastatic prostate cancer or progressive disease on ADT confirmed by prostate-specific antigen (PSA) or imaging. Disease progression at screening is defined as 1 or more of the following 3 criteria:
* PSA progression defined by a minimum of 2 rising PSA levels with an interval of ≥ 1 week between each determination. At least 1 PSA value within the 3 months leading up to the screening period should be ≥ 2μg/L (2 ng/mL).
* Soft tissue disease progression defined by the Response Evaluation Criteria in Solid Tumors, version 1.1 for soft tissue disease.
* Bone disease progression defined by 2 or more new lesions on a bone scan.
* Subject is able to swallow enzalutamide capsules and comply with study requirements.
* Subject has an Eastern Cooperative Oncology Group performance status of 0 to 2.
* Subject with a female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 3 months after final investigational product (IP) administration.
* Subject must not donate sperm during the treatment period and for 3 months after final IP administration.
* Subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 3 months after final IP administration.
* Subject has a body mass index range of 18.5 to 35.0 kg/m2 inclusive. The subject weighs at least 50 kg at screening.
* Subject has an estimated life expectancy of at least 6 months.
* Subject agrees not to participate in another interventional study while receiving IP treatment in the present study/participating in the present study.
Exclusion Criteria
* Subject has any condition, which makes the subject unsuitable for study participation or is not likely to complete the study for any reason.
* Subject has known metastases in the liver or any hepatic disorder that could affect drug metabolism deemed clinically significant.
* Subject is self-reported as Asian.
* Subject has known or suspected brain metastasis or active leptomeningeal disease.
* Subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, brain arteriovenous malformation).
* Subject has a history of loss of consciousness or transient ischemic attack within 12 months of day 1.
* Subject has clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equine syndrome.
* Subject has clinically significant cardiovascular disease including the following:
* Myocardial infarction within 6 months before screening
* Unstable angina within 3 months before screening
* New York Heart Association class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure, unless a screening echocardiogram or multigated acquisition scan performed within 3 months before screening demonstrates a left ventricular ejection fraction ≥ 45%
* History of clinically significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)
* History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
* Hypotension as indicated by systolic blood pressure \< 86 mm Hg at screening
* Bradycardia as indicated by a heart rate of ≤ 45 beats per minute on the screening electrocardiogram (ECG)
* Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure \> 170 mm Hg or diastolic blood pressure \> 105 mm Hg at screening
* Subject has previously received treatment with enzalutamide.
* Subject has undergone major surgery within 4 weeks prior to day 1.
* Subject has a known hypersensitivity reaction to enzalutamide, digoxin, rosuvastatin, contrast agents or any of the components of the formulations used.
* Subject has an absolute neutrophil count \< 1500/μL, platelet count \< 100000/μL and hemoglobin \< 6.2 mmol/L (9 g/dL) during the screening period.
* Subject has received any growth factors or blood transfusions within 7 days prior to the hematologic laboratory values obtained during the screening period.
* Subject has a total bilirubin (TBL) \> 1.5 times the upper limit of normal (ULN) (except for subjects with documented Gilbert's disease), alanine aminotransferase (ALT) \> 2.5 times the ULN or aspartate aminotransferase (AST) \> 2.5 times the ULN during the screening period. Subject with alkaline phosphatase (ALP) \> 3 times ULN will be excluded, unless deemed to be related to bone metastasis, rather than liver disease, and after discussion with the sponsor's medical monitor.
* Subject has an albumin \< 30 g/L (3.0 g/dL) or creatinine \> 177 μmol/L (\> 2 mg/dL) during the screening period.
* Subject has clinical signs and symptoms of hereditary or acquired coagulation disorders within 6 months prior to enrollment (day 1 visit).
* Subject has a history of another invasive cancer within 3 years before screening, with the exception of fully treated cancers with a remote probability of recurrence. The medical monitor and investigator must agree that the possibility of recurrence is remote.
* Subject received treatment with chemotherapy within 4 weeks prior to enrollment (day 1) or plans to initiate treatment with chemotherapy during the study.
* Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 28 days or 5 half-lives, whichever is longer, prior to the initiation of screening.
* Subject has a gastrointestinal disorder affecting absorption.
* Subject uses concomitant medications that are inducers or inhibitors of P-gp and/or BCRP or strong CYP2C8 inhibitors or strong CYP3A4 inducers.
* Subject uses digoxin or rosuvastatin or concomitant medications that are contraindicated with digoxin or rosuvastatin.
* Subject has any history or evidence of any clinically significant gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease.
* Subject has used drugs of abuse (if not medically indicated) within 3 months prior to admission to the clinical unit.
* Subject has a history of consuming \> 21 units of alcohol per week within 3 months prior to day -1 (note: 1 unit = 10 g pure alcohol, 250 mL of beer \[5%\], 35 mL of spirits \[35%\] or 100 mL of wine \[12%\]) or the subject tests positive for alcohol at screening or on day -1.
* Subject has known active hepatitis B (hepatitis B surface antigen \[HBsAg\] reactive, associated with positive anti-hepatitis B core and detectable hepatitis B virus DNA), active hepatitis C (hepatitis C virus \[HCV\] RNA \[qualitative\] is detected) or active viral hepatitis A (immunoglobulin M).
* Subject has a positive human immunodeficiency virus type 1 and/or type 2 at screening.
* Subject is an employee of Astellas, the study-related contract research organizations (CRO) or the clinical unit.
* Subject has known metastases in the liver or any hepatic disorder that could affect drug metabolism deemed clinically significant.
* Subject is self-reported as Asian.
* Subject has known or suspected brain metastasis or active leptomeningeal disease.
* Subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, brain arteriovenous malformation).
* Subject has a history of loss of consciousness or transient ischemic attack within 12 months of day 1.
* Subject has clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equine syndrome.
* Subject has clinically significant cardiovascular disease including the following:
* Myocardial infarction within 6 months before screening
* Unstable angina within 3 months before screening
* New York Heart Association class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure, unless a screening echocardiogram or multigated acquisition scan performed within 3 months before screening demonstrates a left ventricular ejection fraction ≥ 45%
* History of clinically significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)
* History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
* Hypotension as indicated by systolic blood pressure \< 86 mm Hg at screening
* Bradycardia as indicated by a heart rate of ≤ 45 beats per minute on the screening electrocardiogram (ECG)
* Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure \> 170 mm Hg or diastolic blood pressure \> 105 mm Hg at screening
* Subject has previously received treatment with enzalutamide.
* Subject has undergone major surgery within 4 weeks prior to day 1.
* Subject has a known hypersensitivity reaction to enzalutamide, digoxin, rosuvastatin, contrast agents or any of the components of the formulations used.
* Subject has an absolute neutrophil count \< 1500/μL, platelet count \< 100000/μL and hemoglobin \< 6.2 mmol/L (9 g/dL) during the screening period.
* Subject has received any growth factors or blood transfusions within 7 days prior to the hematologic laboratory values obtained during the screening period.
* Subject has a total bilirubin (TBL) \> 1.5 times the upper limit of normal (ULN) (except for subjects with documented Gilbert's disease), alanine aminotransferase (ALT) \> 2.5 times the ULN or aspartate aminotransferase (AST) \> 2.5 times the ULN during the screening period. Subject with alkaline phosphatase (ALP) \> 3 times ULN will be excluded, unless deemed to be related to bone metastasis, rather than liver disease, and after discussion with the sponsor's medical monitor.
* Subject has an albumin \< 30 g/L (3.0 g/dL) or creatinine \> 177 μmol/L (\> 2 mg/dL) during the screening period.
* Subject has clinical signs and symptoms of hereditary or acquired coagulation disorders within 6 months prior to enrollment (day 1 visit).
* Subject has a history of another invasive cancer within 3 years before screening, with the exception of fully treated cancers with a remote probability of recurrence. The medical monitor and investigator must agree that the possibility of recurrence is remote.
* Subject received treatment with chemotherapy within 4 weeks prior to enrollment (day 1) or plans to initiate treatment with chemotherapy during the study.
* Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 28 days or 5 half-lives, whichever is longer, prior to the initiation of screening.
* Subject has a gastrointestinal disorder affecting absorption.
* Subject uses concomitant medications that are inducers or inhibitors of P-gp and/or BCRP or strong CYP2C8 inhibitors or strong CYP3A4 inducers.
* Subject uses digoxin or rosuvastatin or concomitant medications that are contraindicated with digoxin or rosuvastatin.
* Subject has any history or evidence of any clinically significant gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease.
* Subject has used drugs of abuse (if not medically indicated) within 3 months prior to admission to the clinical unit.
* Subject has a history of consuming \> 21 units of alcohol per week within 3 months prior to day -1 (note: 1 unit = 10 g pure alcohol, 250 mL of beer \[5%\], 35 mL of spirits \[35%\] or 100 mL of wine \[12%\]) or the subject tests positive for alcohol at screening or on day -1.
* Subject has known active hepatitis B (hepatitis B surface antigen \[HBsAg\] reactive, associated with positive anti-hepatitis B core and detectable hepatitis B virus DNA), active hepatitis C (hepatitis C virus \[HCV\] RNA \[qualitative\] is detected) or active viral hepatitis A (immunoglobulin M).
* Subject has a positive human immunodeficiency virus type 1 and/or type 2 at screening.
* Subject is an employee of Astellas, the study-related contract research organizations (CRO) or the clinical unit.
Minimum Eligible Age
18 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Sponsor Role
collaborator
Astellas Pharma Global Development, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Global Development, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site MD37301
Chisinau, , Moldova
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Moldova
References
Explore related publications, articles, or registry entries linked to this study.
Poondru S, Ghicavii V, Khosravan R, Manchandani P, Heo N, Moy S, Wojtkowski T, Patton M, Haas GP. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022 May;15(5):1131-1142. doi: 10.1111/cts.13229. Epub 2022 Feb 4.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://www.clinicaltrials.astellas.com/study/?pid=9785-CL-0018
Link to results and other applicable study documents on the Astellas Clinical Trials website
https://www.trialsummaries.com/Study/StudyDetails?id=14668&tenant=MT_AST_9011
Link to plain language summary of the study on the Trial Results Summaries website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9785-CL-0018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
NCT01902251
COMPLETED
PHASE1
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
NCT01212991
COMPLETED
PHASE3
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
NCT01534052
COMPLETED
PHASE2
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
NCT01650194
COMPLETED
PHASE2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022
RECRUITING
PHASE2
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT02124668
COMPLETED
PHASE2
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
NCT02592317
ACTIVE_NOT_RECRUITING
PHASE1
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
NCT02003924
COMPLETED
PHASE3
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
NCT06257693
RECRUITING
PHASE1
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
NCT02288247
COMPLETED
PHASE3
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
NCT05404139
RECRUITING
PHASE2
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01663415
WITHDRAWN
PHASE2
An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
NCT02294461
COMPLETED
PHASE3
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
NCT00541281
COMPLETED
PHASE2
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
NCT02642913
COMPLETED
PHASE1
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
NCT01664923
COMPLETED
PHASE2
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
NCT01352208
TERMINATED
PHASE1/PHASE2
Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects
NCT03927391
COMPLETED
PHASE4
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
NCT03829930
TERMINATED
PHASE1
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT05726292
RECRUITING
PHASE2
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
NCT01990196
ACTIVE_NOT_RECRUITING
PHASE2
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
NCT00055471
COMPLETED
PHASE2
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
NCT02225093
COMPLETED
PHASE1
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
NCT00090363
COMPLETED
PHASE2
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
NCT05873192
RECRUITING
PHASE2